March 22, 2017
In healthy, normotensive men, treatment with moxonidine therapy for 6 weeks resulted in a decrease in blood pressure without altering the aldosterone-to-renin ratio, minimizing the risk for false-positive results in screening for primary aldosteronism, according to findings from researchers in Australia.
“Currently, the most popular screening test for [primary aldosteronism] is the plasma aldosterone-to-renin ratio (ARR),” Ashraf H. Ahmed, MBBS, MSc, PhD, of the endocrine hypertension research center at the University of Queensland School of Medicine, and colleagues wrote. “Although considered the most reliable available screening approach, the ARR is not without false positives or negatives. ... Because most antihypertensive medications are known to affect the ARR, it is often necessary to withdraw such interfering agents to enable confident interpretation of results. ... The identification of additional medications that are free of appreciable effects on the ARR would therefore be very worthwhile.”